DOGP 10-K & 10-Q changes, risk factors and insider trading
Dogecoin Cash, Inc. · OTC · Services-Personal Services · CIK 1360442 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
Not available: the section could not be located automatically in one of the filings (non-standard layout or incorporated by reference). See the original filing. Open the filing on SEC.gov.
Management's Discussion & Analysis (MD&A)
New heading “Year Ended December 31, 2025 compared with the Year Ended December 31, 2024”
Removed heading “Fiscal year ended December 31, 2023 compared with fiscal year ended December 31, 2022”
Removed heading “Off Balance Sheet Arrangements”
Largest changes
“The regulatory environment for cryptocurrencies remains uncertain and evolving. Government authorities, including the SEC, CFTC, IRS, and state regulators, may impose new regulations, taxation requirements, or operational restrictions that could impact the valuation, liquidity, and legal status of DOG tokens. The Company’s ability to hold, trade, or integrate DOG into its business operations may be subject to increased scrutiny or evolving compliance obligations.”see in full comparison
“On November 18, 2024, the Company signed an agreement to acquire 600,000,000 Dogecoin Cash (DOG) tokens in exchange for 4,500,000 shares of the Company’s preferred stock. This strategic acquisition supports the Company’s long-term vision of integrating blockchain and cryptocurrency capabilities into its business model and aligns with its focus on digital asset-based solutions. The transaction is expected to enhance the Company’s market position within the digital asset space and complement its existing business operations. …”see in full comparison
“Fiscal year ended December 31, 2023 compared with fiscal year ended December 31, 2022”see in full comparison
“Year Ended December 31, 2025 compared with the Year Ended December 31, 2024”see in full comparison
“Digital assets such as DOG tokens are highly volatile and speculative in nature. The market price of DOG may fluctuate significantly due to regulatory developments, macroeconomic conditions, or technological factors. Under GAAP accounting guidelines, the Company must test these assets for impairment periodically. If the fair value of DOG tokens falls below their recorded value, the Company may be required to recognize substantial non-cash impairment losses, which could negatively impact its financial position and earnings results.”see in full comparison
Full comparison: every changed paragraph (37)
Overview
Dogecoin Cash Inc. operates primarily through its majority-owned subsidiary PrestoCorp, Inc., which conducts telemedicine services through the PrestoDoctor platform.
The Company generates substantially all of its revenue from telemedicine consultation services facilitated through the PrestoDoctor platform.
Digital Asset Initiatives
The Company maintains certain digital asset and blockchain-related initiatives through subsidiaries including DogeSPAC LLC, Meme Coins, Inc., and Dogecoin Treasury, Inc. These activities currently represent exploratory or strategic initiatives and do not constitute a significant source of the Company’s revenue or operating cash flows. The Company’s principal operating business remains the provision of telemedicine services through its majority-owned subsidiary PrestoCorp, Inc.
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, is intended to help the reader understand the Company, our operations, and our present business environment. MD&A is provided as a supplement to, and should be read in conjunction with, our Consolidated Financial Statements and the accompanying Notes thereto. As discussed in more detail under “Forward-Looking Statements” immediately following this document’s Table of Contents, the following discussion contains forward-looking statements that are based on our management’s current expectations, estimates, and projections, which are subject to a number of risks and uncertainties. Our actual results may differ materially from those discussed in these forward-looking statements because of the risks and uncertainties inherent in future events.
Year Ended December 31, 2025 compared with the Year Ended December 31, 2024
Fiscal year ended December 31, 2023 compared with fiscal year ended December 31, 2022
The narrative comparison of the results of operations for the years ended December 31, 2024 and 2023 are based on the following table.
Revenue for the fiscal year ended December 31, 20242025 decreased 32%8% compared to the year ended December 31, 2023.2024. Cost of revenues as a percentage of sales increaseddecreased 5%14% between the years. The reason for the decrease is there is increaseda significant increase in competition for market share in the cannabis tele-medicine industry.
Total operating expenses decreased 28%14% in 20242025 compared with 20232024 which trended down as did revenue in the current year. Decreases in professional fees, depreciation and amortization, wages and salaries, advertising, and generaladvertising and administrative expenses occurred with continuing efforts at cost reduction.expenses. Depreciation and amortization decreased due to patents becoming fully amortized. Advertising costs were reduced by taking a more focused approach to our target markets. PrestoDoctor salaries decreased with an effort to consolidate and reduce employees and officers reducing their salaries. Professional fees increaseddecreased due to ana increasedecrease in legal and accounting. General and administrative expenses increased due to $75,055 in bad debts and an increase in web costs.
Revenue is derived primarily from telemedicine consultation services conducted through the PrestoDoctor platform.
Operating expenses consist primarily of:
• platform development
• physician network support
• professional fees
• marketing and administrative expenses.
Cash used in operating activities was $107,670$39,583 in 20242025 compared to $63,111$107,671 in 2023.2024. In 2024,2025, financing activities provided $60,092,$34,202 consistingcompared ofto proceeds from related party notes payable$60,092 in the net amount of $22,092, and proceeds from convertible notes payable in the amount of $38,000.2024. We ended 20242025 with $34,934$29,553 in cash on hand.
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We incurred net income (loss) of $188,044,760$10,043,831 and $(1,322,917)$1,780,240 respectively, for the years ended December 31, 2024,2025, and 20232024 and had an accumulated earningsdeficit of $106,008,427$84,389,964 as of December 31, 2024.2025. The Company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt. It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.
The Company has historically funded operations through telemedicine revenues and financing transactions.
Future expansion of the Company’s operations may require additional capital.
The amount of cash on hand the Company has does not provide sufficient liquidity to meet all of the immediate needs of our current operations.
On November 18, 2024, the Company signed an agreement to acquire 600,000,000 Dogecoin Cash (DOG) tokens in exchange for 4,500,000 shares of the Company’s preferred stock. This strategic acquisition supports the Company’s long-term vision of integrating blockchain and cryptocurrency capabilities into its business model and aligns with its focus on digital asset-based solutions. The transaction is expected to enhance the Company’s market position within the digital asset space and complement its existing business operations. The Company will periodically assess the carrying value of these assets for impairment, with any reductions in fair value below cost recognized as an impairment charge in the financial statements. As the cryptocurrency market is highly volatile, the valuation of these assets may experience significant fluctuations over time. The Company is evaluating operational use cases for the acquired DOG tokens, including potential payments integration, investment diversification, or strategic partnerships within the blockchain sector. The Company is also assessing tax implications, liquidity strategies, and regulatory compliance considerations associated with holding and utilizing these digital assets.
Item 1A – Risk Factors
Risks Related to Digital Asset Acquisition
1.Market Volatility and Fair Value Adjustments
Digital assets such as DOG tokens are highly volatile and speculative in nature. The market price of DOG may fluctuate significantly due to regulatory developments, macroeconomic conditions, or technological factors. Under GAAP accounting guidelines, the Company must test these assets for impairment periodically. If the fair value of DOG tokens falls below their recorded value, the Company may be required to recognize substantial non-cash impairment losses, which could negatively impact its financial position and earnings results.
2. Regulatory and Legal Uncertainty
The regulatory environment for cryptocurrencies remains uncertain and evolving. Government authorities, including the SEC, CFTC, IRS, and state regulators, may impose new regulations, taxation requirements, or operational restrictions that could impact the valuation, liquidity, and legal status of DOG tokens. The Company’s ability to hold, trade, or integrate DOG into its business operations may be subject to increased scrutiny or evolving compliance obligations.
3. Liquidity Constraints and Trading Limitations
Unlike traditional financial instruments, cryptocurrencies are not universally accepted as legal tender and may have limited liquidity in certain markets. The Company’s ability to convert DOG tokens into fiat currency or other digital assets may be constrained by market conditions, exchange trading volumes, or operational restrictions. A lack of liquidity could impact the Company’s ability to monetize the acquired digital assets efficiently.
4. Cybersecurity and Custody Risks
Digital assets are subject to theft, hacking, cyber fraud, and technological vulnerabilities. The Company will endeavor to implement security protocols, including multi-signature wallets, cold storage solutions, and encryption measures, to mitigate these risks. However, no system is completely secure, and any unauthorized access or loss of DOG tokens could result in material financial and reputational damage to the Company.
5. Operational and Accounting Challenges
The integration of digital assets into CBDS’s financial reporting and operations introduces complexities in accounting treatment, internal controls, and tax reporting. The Company is evaluating the impact of this acquisition on its financial disclosures, risk management processes, and liquidity planning to ensure full compliance with GAAP, SEC reporting standards, and IRS taxation guidelines.
The amount of cash on hand the Company has does not provide sufficient liquidity to meet all of the immediate needs of our current operations.
Off Balance Sheet Arrangements
What changed in the latest 10-Q
Risk Factors
We could not find a separate Risk Factors item in the latest 10-Q. Some companies leave it out of quarterly reports; see the annual 10-K risk factors and the original filing. Open the filing on SEC.gov.
Management's Discussion & Analysis (MD&A)
New heading “Six Months Ended June 30, 2026 compared with the Six Months Ended June 30, 2025”
Largest changes
“Six Months Ended June 30, 2026 compared with the Six Months Ended June 30, 2025”see in full comparison
“Revenue for the six months ended June 30, 2026, decreased 5% compared to the six months ended June 30, 2025. Cost of revenues as a percentage of sales decreased 7% between the periods. The decrease in revenues is primarily a result of the significant increase in competition for market share in the cannabis tele-medicine industry. This decrease in the demand for our service continued during the second quarter of 2026.”see in full comparison
“Total operating expenses decreased in June 30, 2026 compared with 2025 which trended down as did revenue in the current period. Increases in professional fees were offset by decreases in wages and salaries and general and administrative expenses. PrestoDoctor management salaries also decreased during the six months ended June 30, 2026.”see in full comparison
Total operating expensessee in full comparisonincreaseddecreased30%29% to$283,381$217,515 for the three months endedMarchJune31,30, 2026, compared to$218,581$304,892 inQ1Q2 2025. Theincreasedecrease was driven by a140%42%rise in professional fees and an 18% increasedecrease in general and administrative expenses,partially offset bya7%11%declinedecrease in wages and salaries andana83%6%reductiondecrease inadvertising.professionalDepreciation and amortization was unchanged at $301.fees.
Revenue for the three months endedsee in full comparisonMarchJune31,30, 2026,increaseddecreased5%13% compared to the three months endedMarchJune31,30, 2025. Cost of revenues as a percentage of sales decreased5%13% between the periods. The5%13% revenueincreasedecrease wasachievedthedespiteresult of sustained competitive pressure in the cannabis tele-medicine industry, where intensifying market competition has compressed demand growth through thefirstsecond quarter of 2026."
The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We incurred net losses ofsee in full comparison$200,470$338,176 and$107,364,$7,402,698, respectively, for thethreesix months endedMarchJune31,30, 2026 and 2025 and had an accumulated deficit of$84,587,856$84,714,880 as ofMarchJune31,30, 2026. The Company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt. It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.
Full comparison: every changed paragraph (8)
Three Months Ended MarchJune 31,30, 2026 compared with the Three Months Ended MarchJune 31,30, 2025
Revenue for the three months ended MarchJune 31,30, 2026, increaseddecreased 5%13% compared to the three months ended MarchJune 31,30, 2025. Cost of revenues as a percentage of sales decreased 5%13% between the periods. The 5%13% revenue increasedecrease was achievedthe despiteresult of sustained competitive pressure in the cannabis tele-medicine industry, where intensifying market competition has compressed demand growth through the firstsecond quarter of 2026."
Total operating expenses increaseddecreased 30%29% to $283,381$217,515 for the three months ended MarchJune 31,30, 2026, compared to $218,581$304,892 in Q1Q2 2025. The increasedecrease was driven by a 140%42% rise in professional fees and an 18% increasedecrease in general and administrative expenses, partially offset by a 7%11% declinedecrease in wages and salaries and ana 83%6% reductiondecrease in advertising.professional Depreciation and amortization was unchanged at $301.fees.
Six Months Ended June 30, 2026 compared with the Six Months Ended June 30, 2025
Revenue for the six months ended June 30, 2026, decreased 5% compared to the six months ended June 30, 2025. Cost of revenues as a percentage of sales decreased 7% between the periods. The decrease in revenues is primarily a result of the significant increase in competition for market share in the cannabis tele-medicine industry. This decrease in the demand for our service continued during the second quarter of 2026.
Total operating expenses decreased in June 30, 2026 compared with 2025 which trended down as did revenue in the current period. Increases in professional fees were offset by decreases in wages and salaries and general and administrative expenses. PrestoDoctor management salaries also decreased during the six months ended June 30, 2026.
Cash used in operating activities was $13,443$22,132 in the threesix months ended MarchJune 31,30, 2026. We ended the firstsecond quarter of 2026 with $19,510$10,971 in cash on hand.
The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We incurred net losses of $200,470$338,176 and $107,364,$7,402,698, respectively, for the threesix months ended MarchJune 31,30, 2026 and 2025 and had an accumulated deficit of $84,587,856$84,714,880 as of MarchJune 31,30, 2026. The Company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt. It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.
DOGP insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 1 Form 4 filing (1 insider, 1 trade date, 125,000 shares, about $1.2K) and open-market sales in 7 filings (1 insider, 11 trade dates, 2,421,428 shares, about $34.2K). Net open-market shares: -2,296,428 (purchases minus sales); net value about -$33.0K.Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
| Trade date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-24 | Tobias David |
Open-market sale | 319,170 | $0.01 | $3.2K |
| 2026-09-17 | Tobias David |
Open-market sale | 125,000 | $0.09 | $11.2K |
| 2026-09-17 | Tobias David |
Open-market purchase | 125,000 | $0.01 | $1.2K |
| 2026-09-17 | Tobias David |
Open-market sale | 180,000 | $0.01 | $1.8K |
| 2026-09-10 | Tobias David |
Open-market sale | 100,000 | $0.01 | $1.0K |
| 2026-09-09 | Tobias David |
Open-market sale | 200,000 | $0.01 | $2.0K |
| 2026-07-22 | Tobias David |
Open-market sale | 149,538 | $0.01 | $1.5K |
| 2026-07-20 | Tobias David |
Open-market sale | 97,920 | $0.01 | $979 |
| 2026-07-17 | Tobias David |
Open-market sale | 100,000 | $0.01 | $1.0K |
| 2026-06-30 | Tobias David |
Open-market sale | 150,000 | $0.01 | $1.5K |
| 2026-06-22 | Tobias David |
Open-market sale | 200,000 | $0.01 | $2.0K |
| 2026-04-27 | Tobias David |
Open-market sale | 599,800 | $0.01 | $6.0K |
| 2026-04-21 | Tobias David |
Open-market sale | 200,000 | $0.01 | $2.0K |
Well-known investors holding DOGP (13F)
None of the 59 investors we track reported a position in their latest 13F.